Detalhe da pesquisa
1.
A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera.
J Gen Virol
; 104(6)2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37310000
2.
IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus.
Immunology
; 162(3): 314-327, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33283275
3.
The Humoral Immune Response Against the gB Vaccine: Lessons Learnt from Protection in Solid Organ Transplantation.
Vaccines (Basel)
; 7(3)2019 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31319553
4.
Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligands-A Role for CCL2.
Front Immunol
; 10: 1679, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31428084
5.
Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
EBioMedicine
; 50: 45-54, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31735553
6.
Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine.
Front Immunol
; 10: 1015, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31156619
7.
Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System.
Vaccines (Basel)
; 6(3)2018 Jul 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30004398
8.
Harnessing Nanoparticles for Immunomodulation and Vaccines.
Vaccines (Basel)
; 5(1)2017 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28216554
9.
Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.
J Control Release
; 251: 92-100, 2017 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28257987
10.
Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines.
Front Immunol
; 8: 226, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28321220
11.
Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.
Vaccines (Basel)
; 5(4)2017 Sep 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28953265
12.
Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.
Vaccines (Basel)
; 5(2)2017 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28468322